2011
DOI: 10.1002/ajmg.a.34311
|View full text |Cite
|
Sign up to set email alerts
|

A novel Xp22.11 deletion causing a syndrome of craniosynostosis and periventricular nodular heterotopia

Abstract: We report on a follow-up evaluation of a male with a phenotype including craniosynostosis, periventricular nodular heterotopia, and neurodevelopmental delay. He was initially assigned a clinical diagnosis of Fontaine-Farriaux syndrome (FFS) as an infant although now, with improved delineation of this entity, it is evident that this diagnosis is not applicable to this individual. Array comparative genomic hybridization has demonstrated a 300  kb interstitial deletion on Xp22.11 affecting all or part of three an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 20 publications
0
1
0
Order By: Relevance
“…Mutations in X-linked filamin A (FLNA) [Lange et al, 2015] and ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2) [Bardón-Cancho et al, 2014] are the most common causes of gray matter heterotopias. In addition, other rare causes have also been reported, such as deletions of 1p36 [Neal et al, 2006], 11q24 [So et al, 2014], or Xp22.11 [van Kogelenberg et al, 2011] or mutations in the C6orf70 gene [Conti et al, 2013], which have also gotten much attention in our study. C6orf70 (chromosome 6 open reading frame 70) is ubiquitously highly expressed in the brain and is dosage sensitive.…”
Section: Discussionmentioning
confidence: 80%
“…Mutations in X-linked filamin A (FLNA) [Lange et al, 2015] and ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2) [Bardón-Cancho et al, 2014] are the most common causes of gray matter heterotopias. In addition, other rare causes have also been reported, such as deletions of 1p36 [Neal et al, 2006], 11q24 [So et al, 2014], or Xp22.11 [van Kogelenberg et al, 2011] or mutations in the C6orf70 gene [Conti et al, 2013], which have also gotten much attention in our study. C6orf70 (chromosome 6 open reading frame 70) is ubiquitously highly expressed in the brain and is dosage sensitive.…”
Section: Discussionmentioning
confidence: 80%